Pfizer Seeks Patent Covering a Friedreich’s Ataxia Therapy That Resverlogix Has Already Developed
Pfizer is seeking a European patent on a family of compounds that can treat Friedreich’s ataxia by increasing levels of the frataxin protein that is lacking in the disease. It noted in its patent application that Resverlogix has already developed a therapy called apabetalone (RVX-208) that is based on the compounds.